U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaf

Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX d

Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperf

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance inn

Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therap

Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC

Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to

Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers t

GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership;

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances i

Arcturus Therapeutics Holdings Inc. ((the "Company, " "Arcturus, NASDAQ:ARCT), a messeng

Arcturus to Acquire myNEOArcturus has entered into a definitive agreement to acquire myNEO, subject

ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “

Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger R

Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a mes

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

U.S. stock futures rose, while National Beverage and several stocks fell premarket after disappointi

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2

Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:

BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a goo

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's

Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software p

Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market s

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Cons

Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the sec

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the an

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “

Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has been given a consensus reco

Webcast link can be found under Investor Relations/Events section of Arcturus’ website.

Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization

Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about the

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consid

Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing righ

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the an

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag

Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy